Annexon Biosciences (ANNX)
NASDAQ:ANNX
Want to see ANNX full AI Analyst Report?
ANNX Stock Chart & Stats
$6.54
-$0.26(-5.25%)
At close: 4:00 PM EST
$6.54
-$0.26(-5.25%)
Day’s Range― - ―
52-Week Range$1.60 - $7.18
Previous CloseN/A
Volume252.73K
Average Volume (3M)2.66M
Market Cap
$994.94M
Enterprise Value$588.90M
Total Cash (Recent Filing)$238.34M
Total Debt (Recent Filing)$26.20M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding160,474,330
10 Day Avg. Volume2,489,375
30 Day Avg. Volume2,662,802
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)3.68
Price to Sales (P/S)0.00
P/FCF Ratio-4.18
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-317.12
Enterprise Value/Ebitda-2.78
Forecast
1Y Price Target
$15.40Price Target Upside135.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.08
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ReadoutA positive Phase 3 readout for vonaprument in geographic atrophy could establish the therapy as the first to improve vision and serve as a major valuation catalyst.
Mechanism DifferentiationVonaprument's C1q inhibition aims to protect photoreceptors earlier in the disease, which may translate into meaningful vision preservation distinct from existing complement inhibitors.
Regulatory StrategyA coordinated plan for regulatory submissions in the United States and Europe for lead programs could broaden potential patient access and enhance commercial opportunity if approvals are granted.
Bears Say
Binary Outcome RiskReliance on a single pivotal study as the primary stock catalyst creates a binary outcome risk that could produce sharp share price moves if results disappoint.
Market And Indication ChallengeGeographic atrophy is a difficult indication with uncertain commercial uptake, which could limit the long‑term revenue potential even if clinical effects are demonstrated.
Trial Design And Efficacy UncertaintyUncertainties in pivotal trial design and the need to confirm initial visual acuity benefits in larger studies raise the risk that early signals may not be replicated in later testing.
Annexon Biosciences News
ANNX FAQ
What was Annexon Biosciences’s price range in the past 12 months?
Annexon Biosciences lowest stock price was $1.60 and its highest was $7.18 in the past 12 months.
What is Annexon Biosciences’s market cap?
Annexon Biosciences’s market cap is $994.94M.
When is Annexon Biosciences’s upcoming earnings report date?
Annexon Biosciences’s upcoming earnings report date is May 18, 2026 which is in 24 days.
How were Annexon Biosciences’s earnings last quarter?
Annexon Biosciences released its earnings results on Mar 30, 2026. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.313 by $0.033.
Is Annexon Biosciences overvalued?
According to Wall Street analysts Annexon Biosciences’s price is currently Undervalued.
Does Annexon Biosciences pay dividends?
Annexon Biosciences does not currently pay dividends.
What is Annexon Biosciences’s EPS estimate?
Annexon Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Annexon Biosciences have?
Annexon Biosciences has 160,474,330 shares outstanding.
What happened to Annexon Biosciences’s price movement after its last earnings report?
Annexon Biosciences reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.313. Following the earnings report the stock price went up 11.694%.
Which hedge fund is a major shareholder of Annexon Biosciences?
Currently, no hedge funds are holding shares in ANNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Annexon Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.40 (135.47% Upside)
$15.40 (135.47% Upside)
Blogger Sentiment
Bullish
ANNX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $313.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
347.94%
12-Months-Change
Fundamentals
Return on Equity
-101.33%
Trailing 12-Months
Asset Growth
-20.71%
Trailing 12-Months
Company Description
Annexon Biosciences
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
ANNX Stock 12 Month Forecast
Average Price Target
$15.40
▲(135.47% Upside)
Technical Analysis
Galectin Therapeutics
―
Aldeyra Therapeutics
―
Editas Medicine
―
Alector
―
Neumora Therapeutics, Inc.
―
Ownership Overview
6.85% Insiders
17.23% Mutual Funds
0.02% Other Institutional Investors
63.31% Public Companies and
Individual Investors